Evidence map›Paper›PMID 37944543›Full record

ReviewThe Lancet. Infectious diseases2024

Re-visiting humoral constitutive antibacterial heterogeneity in bloodstream infections.

Ryuichiro Abe, Nikhil Ram-Mohan, Samuel Yang

Abstract readReview
In one paragraph

Review in The Lancet. Infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Poor Glycemic Control in Carbapenem-ResistantInfection and drug resistance · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryuichiro AbeDepartment of Emergency Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
Nikhil Ram-MohanDepartment of Emergency Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
Samuel YangDepartment of Emergency Medicine, Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address: syang5@stanford.edu.
Stanford University · US

Funding

Changing Cultures in Sepsis: Rapid single-cell pathogen identification and antibiotic susceptibility testing directly from whole bloodR01AI153133 · NIAID · STANFORD UNIVERSITY · PI WONG, PAK KIN, YANG, SAMUEL · 2020 to 2024
$3.7M
A "Culture" Shift: Integrated Bacterial Screening and Antibacterial Susceptibility Test on Microfluidic Digital Array for Bloodstream InfectionsR01AI137272 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WANG, TZA-HUEI JEFF, YANG, SAMUEL · 2018 to 2022
$3.6M
Circulating Bacteriophages for the Diagnosis of SepsisR21GM147838 · NIGMS · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L, YANG, SAMUEL · 2022 to 2023
$429k
NIAID NIH HHS R01 AI137272NIAID NIH HHS R01 AI153133NIGMS NIH HHS R21 GM147838
6 · The paper itself

Abstract

Although cellular immunity has garnered much attention in the era of single-cell technologies, humoral innate immunity has receded in priority due to its presumed limited roles. Hence, despite the long-recognised bactericidal activity of serum-a functional characteristic of constitutive humoral immunity-much remains unclear regarding mechanisms underlying its inter-individual heterogeneity and clinical implications in bloodstream infections. Recent work suggests that the immediate antimicrobial effect of humoral innate immunity contributes to suppression of the excessive inflammatory responses to infection by reducing the amount of pathogen-associated molecular patterns. In this Personal View, we propose the need to re-explore factors underlying the inter-individual heterogeneity in serum antibacterial competence as a new approach to better understand humoral innate immunity and revisit the clinical use of measuring serum antibacterial activity in the management of bacterial bloodstream infections. Given the current emphasis on subtyping sepsis, a serum bactericidal assay might prove useful in defining a distinct sepsis endotype, to enable more personalised management.

Indexed as

Bacterial InfectionsSepsisAnti-Bacterial AgentsBacteriaHumansImmunity, InnateAnti-Bacterial Agents

Identifiers

PMID37944543
PMCPMC13591938
OpenAlexW4388405289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.